Brentuximab vedotin plus dacarbazine or nivolumab in classical Hodgkin lymphoma; loss of CD20 causes resistance to mosunetuzumab in r/r B-cell lymphomas; trogocytosis as a driver of RBC antigen loss
Blood Podcast
00:00
Exploring CD20 Loss and Treatment Resistance in B-cell Lymphomas
This chapter delves into the impact of CD20 loss as a mechanism of resistance to therapies like Mosunutuzumab in relapsed refractory B-cell lymphomas. It discusses a study on CD20 modulation patterns, progression events, and the therapeutic implications, highlighting the importance of evaluating CD20 expression for treatment decisions and exploring strategies to overcome resistance.
Transcript
Play full episode
